Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Asset Writedowns and Impairment (2023 - 2024)

Kiora Pharmaceuticals (KPRX) has disclosed Asset Writedowns and Impairment for 3 consecutive years, with -$8000.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Asset Writedowns and Impairment changed N/A year-over-year to -$8000.0, compared with a TTM value of $1.9 million through Sep 2025, changed N/A, and an annual FY2024 reading of $2.0 million, changed N/A over the prior year.
  • Asset Writedowns and Impairment was -$8000.0 for Q4 2024 at Kiora Pharmaceuticals, down from $1.9 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $1.9 million in Q3 2023 and bottomed at -$8000.0 in Q4 2024.